#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pancreatic carcinoma metastatic Autoimmune myositis Acute graft versus host disease Gestational trophoblastic tumour Metabolic disorder Non-small cell lung cancer recurrent Extra-osseous Ewing's sarcoma Adrenocortical carcinoma Hereditary haemorrhagic telangiectasia Angiosarcoma recurrent Obliterative bronchiolitis Glomerulonephritis membranoproliferative Waldenstrom's macroglobulinaemia recurrent Non-Hodgkin's lymphoma Hypochondroplasia More trials…

    Learn about Rare Diseases

    Alagille syndrome – Treatment Undifferentiated sarcoma – Life with Disease Pulmonary sarcoidosis – Basic Information Medulloblastoma recurrent Haemophilia A without inhibitors – Diagnostics Tuberous sclerosis complex – Treatment Breast angiosarcoma – Treatment Primary immunodeficiency syndrome – Diagnostics Langerhans’ cell histiocytosis – Treatment Proteus syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mesna Safinamide OXYBUTYNIN HYDROCHLORIDE AZD4360 BMS-986365 PIPOTIAZINE Ecoo18A Buspirone Hydrochloride Zanubrutinib Fluindione Moxifloxacin Rbp030.2 Etrumadenant Ebastine Petosemtamab Ammonium Chloride Filgotinib Letermovir Sulfamethoxazole Noradrenaline Tartrate More therapies…

    Learn about Your Condition

    Endocarditis enterococcal Vaginal infection Eye pain Dry mouth Peyronie's disease Migraine with aura Autoimmune disorder Hyperplasia adrenal Inborn error of metabolism Lichen planus Erectile dysfunction Brain stem glioma Asplenia Colorectal cancer stage IV Ophthalmoplegia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer

  • Study of MK-5684 compared to standard therapy in patients with breast cancer, ovarian cancer, or endometrial cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Ovarian cancer
    • Breast cancer
    Investigated Drugs:
    • Fludrocortisone Acetate
    • Hydrocortisone Acetate
    • Medroxyprogesterone Acetate
    Spain

  • Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    • Gd2Il18Cart
    Germany

  • Study of inavolisib, letrozole and ribociclib in untreated early-stage breast cancer patients with PIK3CA mutation

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Inavolisib
    • Letrozole
    • Ribociclib
    Germany Spain

  • Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Denosumab
    Austria Germany Spain

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Exemestane
    Austria Belgium France Germany Italy The Netherlands +3

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    Belgium Germany Portugal
Previous Page
1 2 3 4 5 6 … 28
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!